Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Autosomal dominant hypercholesterolemia (ADH; OMIM144400), a risk factor for coronary heart disease, is characterized by an increase in low-density lipoprotein cholesterol levels that is associated with mutations in the genes LDLR (encoding low-density lipoprotein receptor) or APOB (encoding apolipoprotein B). We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin type 9) that cause ADH. PCSK9 encodes NARC-1 (neural apoptosis regulated convertase), a newly identified human subtilase that is highly expressed in the liver and contributes to cholesterol homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [7]
In the citing paper
“In 2003, Abifadel and colleagues identified gain-of-function mutations in the PCSK9 gene causative of familial hypercholesterolemia, an autosomal dominant trait characterized by an elevation in circulating low-density lipoprotein cholesterol (LDL-C) and premature coronary heart disease (CHD) risk (2).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [2]
In the citing paper
“Autosomal Dominant Hypercholesterolemia (ADH), due to mutations in the LDLR, APOB or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to high levels of low-density lipoproteins (LDL).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“ADH is genetically heterogeneous and associated with mutations in the well-known LDLR (low density lipoprotein receptor) (FH, OMIM #606945), APOB (apolipoprotein B-100) (FDB, OMIM # 144010) and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9, Abifadel M et al. 2003) genes.”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the APOE p.Leu167del Mutation (2013) · cites this paper as Abifadel M et al. 2003
In the citing paper
“Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the subtilisin family of proprotein convertases (PCs) [2], with an established role in the systemic control of blood cholesterol and a lesser-characterized role in neuronal development and apoptosis [3,4].”
From PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling (2012) · cites this paper as [3]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
RGD AND OTHER RECOGNITION SEQUENCES FOR INTEGRINS
Ruoslahti, E. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.697 · Cited by 3,191
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Self-citationA proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
Brown, M. S., & Goldstein, J. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.11041 · Cited by 1,134
A Third Major Locus for Autosomal Dominant Hypercholesterolemia Maps to 1p34.1-p32
Varret, M., Rabès, J.-P., Saint-Jore, B., Cenarro, A., Marinoni, J.-C., Civeira, F., Devillers, M., Krempf, M., Coulon, M., Thiart, R., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302370 · Cited by 175
Self-citationBiosynthesis and Cellular Trafficking of the Convertase SKI-1/S1P
Elagoz, A., Benjannet, S., Mammarbassi, A., Wickham, L., & Seidah, N. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109011200 · Cited by 113
Self-citationHunt, S. C., Hopkins, P. N., Bulka, K., McDermott, M. T., Thorne, T. L., Wardell, B. B., Bowen, B. R., Ballinger, D. G., Skolnick, M. H., & Samuels, M. E. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.4.1089 · Cited by 109
Cited by
Items 201–300 of 1,044
Naoumova, R. P., Tosi, I., Patel, D., Neuwirth, C., Horswell, S. D., Marais, A. D., van Heyningen, C., & Soutar, A. K. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000190668.94752.ab · Cited by 182
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation
Fisher, T. S., Surdo, P. L., Pandit, S., Mattu, M., Santoro, J. C., Wisniewski, D., Cummings, R. T., Calzetta, A., Cubbon, R. M., Fischer, P. A., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701634200 · Cited by 181
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
Proprotein Convertases in Health and Disease
Artenstein, A. W., & Opal, S. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1106700 · Cited by 180
Comparison of Genetic Versus Clinical Diagnosis in Familial Hypercholesterolemia
Civeira, F., Ros, E., Jarauta, E., Plana, N., Zambon, D., Puzo, J., Martinez de Esteban, J. P., Ferrando, J., Zabala, S., Almagro, F., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.06.056 · Cited by 180
Sahebkar, A., & Watts, G. F. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.06.019 · Cited by 180
Recent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
Kandaswamy, E., & Zuo, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020424 · Cited by 180
Yuan, J., Cai, T., Zheng, X., Ren, Y., Qi, J., Lu, X., Chen, H., Lin, H., Chen, Z., Liu, M., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00821-2 · Cited by 157
Sun, H., Samarghandi, A., Zhang, N., Yao, Z., Xiong, M., & Teng, B.-B. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.250043 · Cited by 179
Local effects of human PCSK9 on the atherosclerotic lesion
Giunzioni, I., Tavori, H., Covarrubias, R., Major, A. S., Ding, L., Zhang, Y., DeVay, R. M., Hong, L., Fan, D., Predazzi, I. M., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4630 · Cited by 179
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
Tavori, H., Fan, D., Blakemore, J. L., Yancey, P. G., Ding, L., Linton, M. F., & Fazio, S. (2013) · Circulation · doi:10.1161/circulationaha.113.001592 · Cited by 178
Damgaard, D., Larsen, M. L., Nissen, P. H., Jensen, J. M., Jensen, H. K., Soerensen, V. R., Jensen, L. G., & Faergeman, O. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.001 · Cited by 178
RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
Thakore, P. I., Kwon, J. B., Nelson, C. E., Rouse, D. C., Gemberling, M. P., Oliver, M. L., & Gersbach, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04048-4 · Cited by 178
The proprotein convertases are potential targets in the treatment of dyslipidemia
Seidah, N. G., & Prat, A. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0172-7 · Cited by 178
Self-citationThe Severe Hypercholesterolemia Phenotype
Sniderman, A. D., Tsimikas, S., & Fazio, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.060 · Cited by 177
Seidah, N. G., Sadr, M. S., Chrétien, M., & Mbikay, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.481549 · Cited by 177
Self-citationThe LDL cumulative exposure hypothesis: evidence and practical applications
Ference, B. A., Braunwald, E., & Catapano, A. L. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01039-5 · Cited by 176
Guidelines for the Management of Familial Hypercholesterolemia
Harada-Shiba, M., Arai, H., Oikawa, S., Ohta, T., Okada, T., Okamura, T., Nohara, A., Bujo, H., Yokote, K., Wakatsuki, A., et al. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14621 · Cited by 176
Genetic and molecular architecture of familial hypercholesterolemia
Abifadel, M., & Boileau, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13577 · Cited by 176
Self-citationGeorges, A., Bonneau, J., Bonnefont-Rousselot, D., Champigneulle, J., Rabès, J. P., Abifadel, M., Aparicio, T., Guenedet, J. C., Bruckert, E., Boileau, C., et al. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-1 · Cited by 175
Self-citationCatapano, A. L., & Papadopoulos, N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.044 · Cited by 152
Gupta, N., Fisker, N., Asselin, M.-C., Lindholm, M., Rosenbohm, C., Ørum, H., Elmén, J., Seidah, N. G., & Straarup, E. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010682 · Cited by 174
Self-citationUpdate of the molecular basis of familial hypercholesterolemia in The Netherlands
Fouchier, S. W., Kastelein, J. J. P., & Defesche, J. C. (2005) · Human Mutation · doi:10.1002/humu.20256 · Cited by 154
Kessler, T., Vilne, B., & Schunkert, H. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506174 · Cited by 173
Universal Screening for Familial Hypercholesterolemia in Children
Klančar, G., Grošelj, U., Kovač, J., Bratanič, N., Bratina, N., Trebušak Podkrajšek, K., & Battelino, T. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.017 · Cited by 151
Functional characterization of Narc 1, a novel proteinase related to proteinase K
Naureckiene, S., Ma, L., Sreekumar, K. R., Purandare, U., Lo, C. F., Huang, Y., Chiang, L. W., Grenier, J. M., Ozenberger, B. A., Jacobsen, J. S., et al. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.09.011 · Cited by 173
Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells
McNutt, M. C., Kwon, H. J., Chen, C., Chen, J. R., Horton, J. D., & Lagace, T. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808802200 · Cited by 154
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Bergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
PCSK9 Biology and Its Role in Atherothrombosis
Barale, C., Melchionda, E., Morotti, A., & Russo, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115880 · Cited by 171
Chaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 171
APOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170
Self-citationBallantyne, C. M., Neutel, J., Cropp, A., Duggan, W., Wang, E. Q., Plowchalk, D., Sweeney, K., Kaila, N., Vincent, J., & Bays, H. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.02.006 · Cited by 170
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression #
Labonté, P., Begley, S., Guévin, C., Asselin, M.-C., Nassoury, N., Mayer, G., Prat, A., & Seidah, N. G. (2009) · Hepatology · doi:10.1002/hep.22911 · Cited by 153
Self-citationSun, X.-M., Eden, E. R., Tosi, I., Neuwirth, C. K., Wile, D., Naoumova, R. P., & Soutar, A. K. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi128 · Cited by 150
Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
Benito-Vicente, A., Uribe, K. B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., & Martin, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113426 · Cited by 130
The Proprotein Convertases, 20 Years Later
Seidah, N. G. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-204-5_3 · Cited by 167
Self-citationSanna, S., Li, B., Mulas, A., Sidore, C., Kang, H. M., Jackson, A. U., Piras, M. G., Usala, G., Maninchedda, G., Sassu, A., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002198 · Cited by 166
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Li, J., Tumanut, C., Gavigan, J.-A., Huang, W.-J., Hampton, E. N., Tumanut, R., Suen, K. F., Trauger, J. W., Spraggon, G., Lesley, S. A., et al. (2007) · Biochemical Journal · doi:10.1042/bj20070664 · Cited by 149
Persson, L., Cao, G., Ståhle, L., Sjöberg, B. G., Troutt, J. S., Konrad, R. J., Gälman, C., Wallén, H., Eriksson, M., Hafström, I., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.214130 · Cited by 165
He, Y., Rodrigues, R. M., Wang, X., Seo, W., Ma, J., Hwang, S., Fu, Y., Trojnár, E., Mátyás, C., Zhao, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci141513 · Cited by 165
Rios, J., Stein, E., Shendure, J., Hobbs, H. H., & Cohen, J. C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq352 · Cited by 165
Hampton, E. N., Knuth, M. W., Li, J., Harris, J. L., Lesley, S. A., & Spraggon, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703402104 · Cited by 148
Cariou, B., May, C. L., & Costet, P. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.018 · Cited by 164
Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia
Fouchier, S. W., Dallinga-Thie, G. M., Meijers, J. C. M., Zelcer, N., Kastelein, J. J. P., Defesche, J. C., & Hovingh, G. K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304660 · Cited by 163
Alborn, W. E., Cao, G., Careskey, H. E., Qian, Y.-W., Subramaniam, D. R., Davies, J., Conner, E. M., & Konrad, R. J. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2007.091280 · Cited by 163
Elosua, R., Sayols-Baixeras, S., Lluís-Ganella, C., & Lucas, G. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s35301 · Cited by 162
Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L., Wiklund, O., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw480 · Cited by 162
Self-citationChen, S. N., Ballantyne, C. M., Gotto, A. M., Tan, Y., Willerson, J. T., & Marian, A. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.051 · Cited by 162
A cholesterol-lowering VLP vaccine that targets PCSK9
Crossey, E., Amar, M. J. A., Sampson, M., Peabody, J., Schiller, J. T., Chackerian, B., & Remaley, A. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.044 · Cited by 148
Le May, C., Kourimate, S., Langhi, C., Chétiveaux, M., Jarry, A., Comera, C., Collet, X., Kuipers, F., Krempf, M., Cariou, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.181586 · Cited by 161
Self-citationTransgenic mice for in vivo epigenome editing with CRISPR-based systems
Gemberling, M. P., Siklenka, K., Rodriguez, E., Tonn-Eisinger, K. R., Barrera, A., Liu, F., Kantor, A., Li, L., Cigliola, V., Hazlett, M. F., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01207-2 · Cited by 140
Lu, H., & Daugherty, A. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305380 · Cited by 160
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Genetics of Coronary Artery Disease
Roberts, R. (2014) · Circulation Research · doi:10.1161/circresaha.114.302692 · Cited by 159
Aragam, K. G., & Natarajan, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.315928 · Cited by 146
A LIMA1 variant promotes low plasma LDL cholesterol and decreases intestinal cholesterol absorption
Zhang, Y.-Y., Fu, Z.-Y., Wei, J., Qi, W., Baituola, G., Luo, J., Meng, Y.-J., Guo, S.-Y., Yin, H., Jiang, S.-Y., et al. (2018) · Science · doi:10.1126/science.aao6575 · Cited by 158
The missing link between genetic association and regulatory function
Connally, N. J., Nazeen, S., Lee, D., Shi, H., Stamatoyannopoulos, J., Chun, S., Cotsapas, C., Cassa, C. A., & Sunyaev, S. R. (2022) · eLife · doi:10.7554/elife.74970 · Cited by 158
Awan, Z., Seidah, N. G., MacFadyen, J. G., Benjannet, S., Chasman, D. I., Ridker, P. M., & Genest, J. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2011.172932 · Cited by 149
Self-citationRashid, S., Tavori, H., Brown, P. E., Linton, M. F., He, J., Giunzioni, I., & Fazio, S. (2014) · Circulation · doi:10.1161/circulationaha.113.006720 · Cited by 140
Benn, M., & Nordestgaard, B. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy045 · Cited by 130
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
Gallego-Colon, E., Daum, A., & Yosefy, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173114 · Cited by 156
Zhang, Y., Eigenbrot, C., Zhou, L., Shia, S., Li, W., Quan, C., Tom, J., Moran, P., Di Lello, P., Skelton, N. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514067 · Cited by 156
Update on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 155
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
Boudoulas, K. D., Triposkiadis, F. K., Geleris, P., & Boudoulas, H. K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.003 · Cited by 152
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders
Fiorucci, S., Cipriani, S., Baldelli, F., & Mencarelli, A. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.11.001 · Cited by 152
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Sun, X., Essalmani, R., Day, R., Khatib, A. M., Seidah, N. G., & Prat, A. (2012) · Neoplasia · doi:10.1593/neo.121252 · Cited by 135
Self-citationCariou, B., Ouguerram, K., Zaïr, Y., Guerois, R., Langhi, C., Kourimate, S., Benoit, I., Le May, C., Gayet, C., Belabbas, K., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.194191 · Cited by 140
Self-citationTargeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Yamauchi, T., Masuda, T., Canver, M. C., Seiler, M., Semba, Y., Shboul, M., Al-Raqad, M., Maeda, M., Schoonenberg, V. A. C., Cole, M. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.012 · Cited by 138
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
Cui, Q., Ju, X., Yang, T., Zhang, M., Tang, W., Chen, Q., Hu, Y. S., Haas, J. V., Troutt, J. S., Pickard, R. T., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.027 · Cited by 149
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Galabova, G., Brunner, S., Winsauer, G., Juno, C., Wanko, B., Mairhofer, A., Lührs, P., Schneeberger, A., von Bonin, A., Mattner, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114469 · Cited by 138
Mitchell, T. S., Chao, G., Sitkoff, D. F., Lo, F., Monshizadegan, H., Meyers, D. S., Low, S., Russo, K., DiBella, R. A., Denhez, F., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214221 · Cited by 149
Lindholm, M. W., Elmén, J., Fisker, N., Hansen, H. F., Persson, R., Møller, M. R., Rosenbohm, C., Ørum, H., Straarup, E. M., & Koch, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.260 · Cited by 147
Multiplex Ligation-Dependent Probe Amplification
Jeuken, J. W. M., Cornelissen, S. J. B., Boots‐Sprenger, S., Gijsen, S. J., & Wesseling, P. (2006) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2006.060012 · Cited by 147
Bottomley, M. J., Cirillo, A., Orsatti, L., Ruggeri, L., Fisher, T. S., Santoro, J. C., Cummings, R. T., Cubbon, R. M., Lo Surdo, P., Calzetta, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808363200 · Cited by 132
Ni, Y. G., Di Marco, S., Condra, J. H., Peterson, L. B., Wang, W., Wang, F., Pandit, S., Hammond, H. A., Rosa, R., Cummings, R. T., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011445 · Cited by 134
Ganesh, S. K., Arnett, D. K., Assimes, T. L., Basson, C. T., Chakravarti, A., Ellinor, P. T., Engler, M. B., Goldmuntz, E., Herrington, D. M., Hershberger, R. E., et al. (2013) · Circulation · doi:10.1161/01.cir.0000437913.98912.1d · Cited by 127
In vivo evidence that furin from hepatocytes inactivates PCSK9
Essalmani, R., Susan-Resiga, D., Chamberland, A., Abifadel, M., Creemers, J. W., Boileau, C., Seidah, N. G., & Prat, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.192104 · Cited by 144
Self-citationHong, C., Duit, S., Jalonen, P., Out, R., Scheer, L., Sorrentino, V., Boyadjian, R., Rodenburg, K. W., Foley, E., Korhonen, L., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.123729 · Cited by 142
Effect of Evolocumab on Coronary Plaque Composition
Nicholls, S. J., Puri, R., Anderson, T., Ballantyne, C. M., Cho, L., Kastelein, J. J. P., Koenig, W., Somaratne, R., Kassahun, H., Yang, J., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.078 · Cited by 142
The evolution of domain arrangements in proteins and interaction networks
Bornberg‐Bauer, E., Beaussart, F., Kummerfeld, S., Teichmann, S. A., & Weiner, J. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4416-1 · Cited by 142
Fasano, T., Cefalù, A. B., Di Leo, E., Noto, D., Pollaccia, D., Bocchi, L., Valenti, V., Bonardi, R., Guardamagna, O., Averna, M., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000255311.26383.2f · Cited by 128
Inhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Protective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 141
Lintner, N. G., McClure, K. F., Petersen, D., Londregan, A. T., Piotrowski, D. W., Wei, L., Xiao, J., Bolt, M., Loria, P. M., Maguire, B., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001882 · Cited by 128
Peterson, A. S., Fong, L. G., & Young, S. G. (2008) · Journal of Lipid Research · doi:10.1194/jlr.e800008-jlr200 · Cited by 129
Tejedor, D. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.045203 · Cited by 122
Raal, F., Panz, V., Immelman, A., & Pilcher, G. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000028 · Cited by 132
The utility of target-based discovery
Croston, G. E. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1308351 · Cited by 140
Mayer, G., Poirier, S., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805971200 · Cited by 139
Self-citationActivation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Langhi, C., Le May, C., Kourimate, S., Caron, S., Staels, B., Krempf, M., Costet, P., & Cariou, B. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.02.038 · Cited by 113
Self-citationMolecular Pathways Underlying Cholesterol Homeostasis
Afonso, M. S., Machado, R. M., Lavrador, M., Quintao, E. C. R., Moore, K., & Lottenberg, A. (2018) · Nutrients · doi:10.3390/nu10060760 · Cited by 138
Animal Models of Atherosclerosis–Supportive Notes and Tricks of the Trade
Gisterå, A., Ketelhuth, D. F. J., Malin, S., & Hansson, G. K. (2022) · Circulation Research · doi:10.1161/circresaha.122.320263 · Cited by 138
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kysenius, K., Muggalla, P., Mätlik, K., Arumäe, U., & Huttunen, H. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0977-6 · Cited by 137
Evolution and Emergence of Therapeutic Monoclonal Antibodies: What Cardiologists Need to Know
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 136
Metadata
- Authors
- Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derré, A., Villéger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J.-M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., & Boileau, C.
- Affiliations
- Hôpital Necker-Enfants Malades (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Genoscope (FR)
- Montreal Clinical Research Institute (CA)
- Pitié-Salpêtrière Hospital (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Hôpital Claude Huriez (FR)
- Hospices Civils de Lyon (FR)
- ORCID
- Venue
- Nature Genetics
- Published
- 2003-05-05
- Volume
- 34
- Issue
- 2
- Pages
- 154-156
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2040612932
- Semantic Scholar
- 80bf33c74bfe780bcc1968f318b09647e59f0afe
- Cited by
- 2,985
- References
- 6
- Citations by year
- 2026: 88 · 2025: 115 · 2024: 154 · 2023: 175 · 2022: 163 · 2021: 207 · 2020: 182 · 2019: 173 · 2018: 214 · 2017: 232 · 2016: 214 · 2015: 200 · 2014: 162 · 2013: 131 · 2012: 101
- FWCI
- 38.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PCSK9, autosomal dominant hypercholesterolemia, LDL receptor, apolipoprotein B, LDL cholesterol, genetic mutations, cholesterol homeostasis, subtilases, coronary heart disease risk
- MeSH terms
- Proprotein Convertase 9, Chromosomes, Human, Pair 1, Female, Genes, Dominant, Humans, Hyperlipoproteinemia Type II, Genetic Linkage, Liver, Male, Mutation, Pedigree, Serine Endopeptidases, Amino Acid Substitution, Proprotein Convertases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.